Most Recent Articles about AZN
AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why http://www.zacks.com/stock/news/386792/aveo-pharmaceuticals-down-more-than-40-in-90-days-heres-why?cid=CS-ZC-FT-386792 Apr 18, 2019 - AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.
Top Ranked Income Stocks to Buy for April 17th http://www.zacks.com/commentary/382754/top-ranked-income-stocks-to-buy-for-april-17th?cid=CS-ZC-FT-382754 Apr 17, 2019 - Top Ranked Income Stocks to Buy for April 17th
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer http://www.zacks.com/stock/news/380655/clovis-stalls-mid-stage-rubraca-study-for-bladder-cancer?cid=CS-ZC-FT-380655 Apr 15, 2019 - Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.

Related Companies

Name Exchange Price Mkt Cap
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
SNY Sanofi NYSE $43.75 $109.14B
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals